Amgen's Repatha Demonstrates Broad Heart Disease Prevention Success
TL;DR Summary
Amgen announced that its cholesterol-lowering drug Repatha significantly prevented heart disease-related deaths, heart attacks, and strokes in a large 12,000-patient trial, potentially broadening its market beyond high-risk patients and boosting its commercial prospects.
- Amgen says its cholesterol shot prevented heart problems in a broad population statnews.com
- Amgen charts late-stage win for Repatha in broad cardiovascular risk population Fierce Pharma
- Amgen claims ‘landmark’ study result that could widen heart drug’s use Yahoo Finance
- VESALIUS-CV: Evolocumab (Repatha) Achieves of Primary Endpoints in Patients with ASCVD HCPLive
- From Breakthrough Science to Real-World Impact: Amgen's Legacy in Cardiovascular Disease Care Amgen
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
1 min
vs 2 min read
Condensed
88%
275 → 33 words
Want the full story? Read the original article
Read on statnews.com